

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Regenerative Medicine International Limited

中國再生醫學國際有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8158)

- (1) RESIGNATION OF CHIEF FINANCIAL OFFICER, COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE;**
- (2) APPOINTMENT OF NON-EXECUTIVE DIRECTOR;**
- (3) APPOINTMENT OF CHIEF FINANCIAL OFFICER; AND**
- (4) NON-COMPLIANCE WITH GEM LISTING RULES**

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Regenerative Medicine International Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Wong Po Tin (“**Mr. Wong**”) has resigned and will cease to be the Chief Financial Officer, the company secretary and the authorised representative of the Company under Rule 5.24 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (“**GEM Listing Rules**”), the authorised representative for accepting service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and Rule 24.05(2) of GEM Listing Rules with effect from 25 April 2025, due to his other personal commitments. Mr. Wong has confirmed that he has no disagreement with the Board and there is no matter that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholder of the Company in relation to his resignation. The Board would like to take this opportunity to express its sincere gratitude to Mr. Wong for his valuable contributions to the Company during his tenure of office.

The Board is pleased to announce that, with effect from 25 April 2025:

- (a) Ms. Luo Min (雒敏) (“**Ms. Luo**”) will be appointed as the non-executive Director of the Company; and
- (b) Mr. Yan Shibin (嚴仕斌) (“**Mr. Yan**”) will be appointed as the Chief Financial Officer of the Company.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

Ms. Luo, aged 46, has been appointed as a Professor of the School of Health Policy and Management (南京醫科大學醫政學院) (“**SHPM**”) and Associate Director of the Department of Health Economics and Management (醫藥經濟與管理系) (“**Department of HSM**”), of Nanjing Medical University since November 2024. Prior to that, Ms. Luo was the Associate Professor and Head of the Department of Pharmaceutical and Trade Studies of SHPM and Associate Director of the Department of HSM during the period of August 2014 to October 2024, lecturer of SHPM during August 2007 to July 2014, and teaching assistant of SHPM during July 2004 to July 2007.

Ms. Luo graduated from Nanjing Audit University (formerly known as Nanjing Audit Institute) with a Bachelor's Degree in Economics from the Department of Finance in 2001, a Master's Degree in Economics from the Department of Finance from Nanjing University in 2004 and a Doctorate Degree in Management from the Department of Accounting from Nanjing University in 2012. She is also a non-practising member of the Chinese Institute of Certified Public Accountants from 2005, and has been appointed as a council member of the 10th Council of Jiangsu Health Economics Society* (江蘇省衛生經濟學會第十屆理事會理事) since 2003.

Ms. Luo has entered into a letter of appointment with the Company as a non-executive Director of the Company for an initial term of one (1) year with effect from 25 April 2025 unless terminated by at least one (1) month's notice in writing served by either party. Such appointment is subject to retirement by rotation, re-election, removal, vacation or termination of such office in accordance with the articles of association of the Company, the GEM Listing Rules and other applicable laws and regulations.

Pursuant to the letter of appointment, Ms. Luo is entitled to a director's fee of HK\$10,000 per month, which is determined by the Board and the remuneration committee of the Company (the “**Remuneration Committee**”) with reference to her qualifications, experience, role and level of responsibilities undertaken as well as the prevailing market conditions. Such remuneration is subject to annual review by the Remuneration Committee.

Save as disclosed above, as at the date of this announcement, Ms. Luo (i) has not held any other major appointments and professional qualifications or directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (ii) does not hold any other positions with the Company or other members of the Group; (iii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders (having the meaning ascribed to them in the GEM Listing Rules) of the Company; and (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no further information required to be disclosed pursuant to the requirements of Rule 17.50(2) of the GEM Listing Rules and there are no other matters relating to the appointment of Ms. Luo that need to be brought to the attention of the Stock Exchange or the shareholders of the Company.

APPOINTMENT OF CHIEF FINANCIAL OFFICER

Mr. Yan, aged 49, has extensive experience in finance. He graduated from Zhongnan University of Economics and Law (中南財經政法大學) majoring in finance (investment)* (金融學(投資方向)) and obtained a bachelor's degree in economics in 2000. He served as finance controller of Sichuan Jianzhong Kanghua Hospital Management Co., Ltd.* (四川健中康華醫院管理有限公司) during the period of November 2024 to April 2025, chief financial officer of Beijing Aiqihang Network Technology Co., Ltd.* (北京愛啟航網絡科技有限公司) during the period of April 2022 to October 2024, chief financial officer of Beijing Qihang Longtu Education Technology Co., Ltd.* (北京啟航龍圖教育科技有限公司) during the period of January 2021 to March 2022, vice president of finance of Huatai Motor Group Co., Ltd.* (華泰汽車集團有限公司) during the period of May 2016 to December 2020, and chief financial officer of Hanneng New Materials Technology Co., Ltd.* (漢能新材料科技有限公司) during the period of August 2013 to April 2016.

He has also been admitted as a certified internal auditor of the Institute of Internal Auditors since 1 November 2003, a non-practising member of the Chinese Institute of Certified Public Accountants since 9 December 2014, and an international affiliate of the Hong Kong Institute of Certified Public Accountants since 1 January 2025.

NON-COMPLIANCE OF GEM LISTING RULES

Following the resignation of Mr. Wong as the company secretary and an authorised representative, the Company shall have no company secretary, and will not be able to meet the requirements under Rule 5.14 of the GEM Listing Rules and the requirements that every listed issuer shall appoint two authorised representatives under Rule 5.24 of the GEM Listing Rules. In view of this, the Company has been identifying a suitable candidate to fill the vacancies of the company secretary and authorised representative as soon as practicable in accordance with the requirements of the GEM Listing Rules to ensure compliance by the Company with Rules 5.14 and 5.24 of the GEM Listing Rules. The Company will make further announcements as and when appropriate.

The Board would like to express its warmest welcome to Ms. Luo and Mr. Yan for joining the Company.

By Order of the Board
China Regenerative Medicine International Limited
Wang Chuang
Chairman, Chief Executive Officer and Executive Director

Hong Kong, 25 April 2025

As at the date of this announcement, the executive Director is Mr. Wang Chuang (Chairman and Chief Executive Officer); the non-executive Director is Ms. Luo Min; and the independent non-executive Directors are Ms. Huo Chunyu, Dr. Liu Ming and Mr. Leung Man Fai.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkexnews.hk for at least seven days from the date of the publication and will be published on the website of the Company at www.crmi.hk.

* *For identification purpose only*